

VAGINAL DISCHARGE

References

1. Mead PB. Epidemiology of bacterial vaginosis. *Am J Obstet Gynecol* 1993;169(2 Pt 2):446–449.
2. Schmidt H, Hansen JG. Bacterial vaginosis in a family practice population. *Acta Obstet Gynecol Scand* 2000;79:999–1005.
3. Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. *Am J Obstet Gynecol* 2003;189:139–147.
4. Soper DE, Bump RC, Hurt WG. Bacterial vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy. *Am J Obstet Gynecol* 1990;163:1016–1021.
5. Penney GC, Thompson M, Norman J, et al. A randomised comparison of strategies for reducing infective complications of induced abortion. *Br J Obstet Gynaecol* 1998;105:599–604.
6. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. *AIDS* 1998;12:1699–1706.
7. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. *J Infect Dis* 1999;180:1863–1838.
8. Sobel JD. Management of patients with recurrent vulvovaginal candidiasis. *Drugs* 2003;63:1059–1066.
9. [Duerr A](#), [Heilig C](#), [Meikle S](#), et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: risk factors and severity. *Obstet Gynecol* 2003;101:548–556.
10. [McClelland R](#), [Lavreys L](#), [Katingima C](#), et al. Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. *J Infect Dis* 2005;191:333–338.
11. [Ohmit S](#), [Sobel J](#), [Schuman P](#), et al. Longitudinal study of mucosal *Candida* species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. *J Infect Dis* 2003;188:118–127.
12. [Schuman P](#), [Sobel J](#), [Ohmit S](#), et al. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. *Clin Infect Dis* 1998;27:1161–1167.
13. Sorvillo F, Smith L, Kerndt P, Ash L. *Trichomonas vaginalis*, HIV, and African-Americans. *Emerg Infect Dis* 2001;7:927–932.
14. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. *Sex Transm Infect* 1999;75:3–17.
15. Schwebke J. Update of trichomoniasis. *Sex Transm Infect* 2002;78:378–379.
16. Anderson MR, Klink K, Cochrane A. Evaluation of vaginal complaints. *JAMA* 2004;291:1368–1379.
17. World Health Organization. Guidelines for the management of sexually transmitted infections. Geneva; World Health Organization: 2003.

18. Lugo-Miro V, Green M, Mazur L. Comparison of different metronidazole therapeutic regimens for bacterial vaginosis. A meta-analysis. *JAMA* 1992;268:92–95.
19. Hanson JM, McGregor JA, Hillier SL, et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. *J Reprod Med* 2000;45:889–896.
20. Ferris DS, Litaker MS, Woodward L, Mathis D, Hendrich J. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. *J Fam Pract* 1995;41:443–449.
21. Swedberg J, Steiner JF, Deiss F, Steiner S, Driggers DA. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. *JAMA* 1985;254:1046–1049.
22. Sobel JD. Vaginitis. *N Engl J Med* 1997;337:1896–1903.
23. Sobel J. Bacterial vaginosis. *Annu Rev Med* 2000;51:349–356.
24. Alfonsi GA, Shlay JC, Parker S, Neher JO. What is the best approach for managing recurrent bacterial vaginosis? *J Fam Pract* 2004;53:650–652.
25. Guise JM, Mahon SM, Aickin M, Helfand M, Peipert JF, Westhoff C. Screening for bacterial vaginosis in pregnancy. *Am J Prev Med* 2001;20(suppl 3):62–72.
26. McDonald H, Brocklehurst P, Parsons J, Vigneswaran R. Antibiotics for treating bacterial vaginosis in pregnancy. *Cochrane Database Syst Rev* 2003;2:CD000262.
27. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. *Obstet Gynecol* 1993;82:348–352.
28. Czeizel A, Rockenbauer M. A population based case-control teratologic study of oral metronidazole. *Br J Obstet Gynaecol* 1998;105:322–327.
29. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. *Am J Obstet Gynecol* 1995;172(2 Pt 1):525–529.
30. Caro-Paton T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. *Br J Clin Pharmacol* 1997;44:179–182.
31. Passmore CM, McElnay JC, Rainey EA, D'Arcy PF. Metronidazole excretion in human milk and its effect on the suckling neonate. *Br J Clin Pharmacol* 1988;26:45–51.
32. Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). *Cochrane Database Syst Rev* 2001;4:CD002845.
33. Sobel JD, Kapernick PS, Zervos M, et al. Treatment of complicated *Candida* vaginitis: comparison of single and sequential doses of fluconazole. *Am J Obstet Gynecol* 2001;185:363–369.
34. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. *N Engl J Med* 2004;351:876–883.
35. Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. *Am J Obstet Gynecol* 1998;178:203–211.
36. Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of *Candida* vaginitis. Fluconazole Vaginitis Study Group. *Am J Obstet Gynecol* 1995;172(4 Pt 1):1263–1268.
37. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. *Clin Infect Dis* 2000;30:662–678.
38. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. *Clin Infect Dis* 2004;38:161–189.

39. Sobel JD, Chaim W. Treatment of *Torulopsis glabrata* vaginitis: retrospective review of boric acid therapy. *Clin Infect Dis* 1997;24:649–652.
40. Guaschino S, De Seta F, Sartore A, et al. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. *Am J Obstet Gynecol* 2001;184:598–602.
41. Sobel JD. Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. *N Engl J Med* 1986;315:1455–1458.
42. Creatsas GC, Charalambidis VM, Zagotzidou EH, Anthopoulou HN, Michailidis DC, Aravantinos DI. Chronic or recurrent vaginal candidosis: short-term treatment and prophylaxis with itraconazole. *Clin Ther* 1993;15:662–671.
43. Spinillo A, Colonna L, Piazzzi G, Baltaro F, Monaco A, Ferrari A. Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. *J Reprod Med* 1997;42:83–87.
44. Roth AC, Milsom I, Forssman L, Wahlen P. Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet. *Genitourin Med* 1990;66:357–360.
45. Jovanovic R, Congema E, Nguyen HT. Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis. *J Reprod Med* 1991;36:593–597.
46. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by *Candida glabrata*: use of topical boric acid and flucytosine. *Am J Obstet Gynecol* 2003;189:1297–1300.
47. Horowitz BJ. Topical flucytosine therapy for chronic recurrent *Candida tropicalis* infections. *J Reprod Med* 1986;31:821–824.
48. Phillips AJ. Treatment of non-*albicans* *Candida* vaginitis with amphotericin B vaginal suppositories. *Am J Obstet Gynecol* 2005;192:2009–2012.
49. White DJ, Habib AR, Vanthuyne A, Langford S, Symonds M. Combined topical flucytosine and amphotericin B for refractory vaginal *Candida glabrata* infections. *Sex Transm Infect* 2001;77:212–213.
50. Shann S, Wilson J. Treatment of *Candida glabrata* using topical amphotericin B and flucytosine. *Sex Transm Infect* 2003;79:265–266.
51. Fidel PL Jr, Vazquez JA, Sobel JP. *Candida glabrata*: review of epidemiology, pathogenesis, and clinical disease with comparison to *C. albicans*. *Clin Microbiol Rev* 1999;12:80–96.
52. Buch A, Skytte Christensen E. Treatment of vaginal candidosis with natamycin and effect of treating the partner at the same time. *Acta Obstet Gynecol Scand* 1982;61:393–396.
53. Bisschop MP, Merkus JM, Scheygrond H, van Cutsem J. Co-treatment of the male partner in vaginal candidosis: a double-blind randomized control study. *Br J Obstet Gynaecol* 1986;93:79–81.
54. Calderon-Marquez J. Itraconazole in the treatment of vaginal candidosis and the effect of treatment of the sexual partner. *Rev Infect Dis* 1987;9(suppl 1):S143–S145.
55. Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. *Cochrane Database Syst Rev* 2001;4:CD000225.
56. Forna F, Gulmezoglu AM. Interventions for treating trichomoniasis in women. *Cochrane Database Syst Rev* 2003;2:CD000218.

57. Schmid G, Narcisi E, Mosure D, Secor WE, Higgins J, Moreno H. Prevalence of metronidazole-resistant *Trichomonas vaginalis* in a gynecology clinic. *J Reprod Med* 2001;46:545–549.
58. Kigozi GG, Brahmhat H, Wabwire-Mangen F, et al. Treatment of *Trichomonas* in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. *Am J Obstet Gynecol* 2003;189:1398–1400.
59. Gulmezoglu A. Interventions for trichomoniasis in pregnancy. *Cochrane Database Syst Rev* 2002;3:CD000220.
60. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic *Trichomonas vaginalis* infection. *N Engl J Med* 2001;345:487–493.
61. Reid G, Charbonneau D, Erb J, et al. Oral use of *Lactobacillus rhamnosus* GR-1 and *L. fermentum* RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. *FEMS Immunol Med Microbiol* 2003;35:131–134.
62. Pirota M, Gunn J, Chondros P, et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. *BMJ* 2004;329:548.
63. Parent D, Bossens M, Bayot D, et al. Therapy of bacterial vaginosis using exogenously applied *Lactobacilli acidophili* and a low dose of estriol: a placebo-controlled multicentric clinical trial. *Arzneimittelforschung* 1996;46:68–73.
64. Ozkinay E, Terek MC, Yayci M, et al. The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. *BJOG* 2005;112:234–240.

